Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
about
Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy.Beta-lactam antibiotic dosing during continuous renal replacement therapy: how can we optimize therapy?Forecasting carbapenem resistance from antimicrobial consumption surveillance: Lessons learnt from an OXA-48-producing Klebsiella pneumoniae outbreak in a West London renal unit.Pharmacokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treated with continuous venovenous hemodialysis.Antimicrobial dosing in acute renal replacement.Clinical implications of antibiotic pharmacokinetic principles in the critically ill.Compliance With Institutional Antimicrobial Dosing Guidelines in Patients Receiving Continuous Venovenous Hemodialysis.Antibiotic Dosing in Patients With Acute Kidney Injury: "Enough But Not Too Much".Practical considerations to drug dosing in children with acute kidney injury.Therapeutic drug monitoring of anti-infective agents in critically ill patients.Pharmacokinetics and Pharmacodynamics of Extended Infusion Versus Short Infusion Piperacillin-Tazobactam in Critically Ill Patients Undergoing CRRT.Wound Penetration of Cefazolin, Ciprofloxacin, Piperacillin, Tazobactam, and Vancomycin During Negative Pressure Wound Therapy.Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam during high volume haemodiafiltration in patients with septic shock.Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.Staying on target with continuous dialysis.[Hot rods in the ICU : What is the antibiotic mileage of your renal replacement therapy?]Simplifying Piperacillin/Tazobactam Dosing: Pharmacodynamics of Utilizing Only 4.5 or 3.375 g Doses for Patients With Normal and Impaired Renal Function.Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements.
P2860
Q33821554-E3FF08EE-439C-4F10-A3CB-4847005790B0Q33821937-10F88927-A205-4997-A58E-A1C351F338BFQ35921350-94592CEB-D644-4ECD-9ABA-566443F01AF2Q37066774-837B0B97-732B-4BB8-8F56-4D89C26C5CDCQ37252494-1A19D712-8B44-4008-A1DC-945808AC0BD4Q38138835-09A47FBC-87C1-4190-AC9F-F022BEA4FD91Q38181340-B0F38195-4422-4528-A5DC-4A47655D583AQ38261172-200E1203-E345-4F7E-8DCF-BA8EF553DEFBQ38585496-B08DACB8-5B0A-43EC-B1B6-5EBB8CBE13D9Q38790740-19DF3A5E-2921-4817-A4EE-D42A3CF89EDCQ38838763-23F01658-9C32-4198-AAED-E423F04E9868Q38949043-9F2270E2-A81E-452B-9819-E6F9468F725EQ39882067-6BE6D12A-BED1-4B80-85B9-2D442A455576Q40445718-EE4D7CA8-BF4C-4BA7-B261-0791A28CD178Q40810754-EF5A6B2B-0FD1-4B86-948B-5ED2ECB14FC5Q41148311-C6FAB941-9E49-4561-9CBC-69B9A43987BFQ42907574-F87BC937-C8C0-47CE-8A3C-8E43192A33D0Q50032998-8E4BDCC5-D9DD-46EB-86B6-B9156EE00743Q50089280-ACCBC272-1DD2-43EA-BA93-96C51E9BCB72Q50260879-DFFD1C41-FB5E-4963-AF76-62AA1736F1CE
P2860
Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Pharmacokinetics and pharmacod ...... treated with concomitant CRRT.
@ast
Pharmacokinetics and pharmacod ...... treated with concomitant CRRT.
@en
type
label
Pharmacokinetics and pharmacod ...... treated with concomitant CRRT.
@ast
Pharmacokinetics and pharmacod ...... treated with concomitant CRRT.
@en
prefLabel
Pharmacokinetics and pharmacod ...... treated with concomitant CRRT.
@ast
Pharmacokinetics and pharmacod ...... treated with concomitant CRRT.
@en
P2093
P2860
P356
P1476
Pharmacokinetics and pharmacod ...... treated with concomitant CRRT
@en
P2093
Ashita J Tolwani
Charbel Salem
Joseph Groszek
Maria E Taylor
Peilin Wei
Seth R Bauer
William H Fissell
P2860
P304
P356
10.2215/CJN.10741011
P577
2012-01-26T00:00:00Z